Table 1.
Baseline characteristics of participants with and without death in the MrOS cohort.
| Demographics | Death (N = 364) |
Living patients (N = 2,557) |
P |
|---|---|---|---|
| Age (years) (mean ± SD) | 76.1 ± 3.1 | 75.3 ± 3.2 | <0.001 |
| Body mass index (kg/m²) (mean ± SD) | 25.96 ± 3.83 | 26.47 ± 3.51 | 0.011 |
| Smokers, N (%) | 37 (10.2) | 205 (8.0) | 0.161 |
| Comorbidities | |||
| Hypertension, N (%) | 137 (37.6) | 927 (36.3) | 0.570 |
| Diabetes, N (%) | 54 (14.8) | 224 (8.8) | <0.001 |
| Coronary artery disease, N (%) | 74 (20.3) | 340 (13.3) | <0.001 |
| Stroke, N (%) | 37 (10.2) | 150 (5.9) | 0.002 |
| Cancer, N (%) | 88 (24.2) | 359 (14.0) | <0.001 |
| Biochemistry | |||
| eGFR (ml/min/1.73 m²) (mean ± SD) | 66.76 ± 25.01 | 72.85 ± 19.70 | <0.001 |
| Phosphate (mmol/L) (mean ± SD) | 1.09 ± 0.17 | 1.07 ± 0.16 | 0.046 |
| FGF23 (pg/ml) (mean ± SD) | 53.38 ± 46.51 | 48.07 ± 33.39 | 0.009 |
| Deaths N (%) | |||
| All-cause mortality, N (%) | 364 | — | — |
| Mortality rate (incidence rate and 95% CI) a | 26.68 (23.77–29.95) | — | — |
| Cardiovascular mortality, N (%) | 139 (38.2) | — | — |
| Mortality rate (incidence rate and 95% CI)a | 10.93 (9.13–13.09) | — | — |
| Follow up time (years) (mean ± SD) | 2.93 ± 1.36 | 4.71 ± 0.74 | <0.001 |
Normally distributed continuous variables are presented as mean standard deviation and categorical variables as n (%).
aIncidence rate: 1,000 person-year.
eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; SD, standard deviation.